Novartis

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Monday, March 18, 2024
Employment, Development, ARVN, PROTAC, Pfizer, Oncology, Partnership, Novartis, Executive, Patient, Knowledge, National Cancer Institute, Bristol Myers Squibb, BMS, Neuroscience, Columbia University, LRRK2, Pharmaceutical industry

Effective today, Dr. Berkowitz will lead the ongoing clinical development of Arvinas’ PROTAC® protein degrader programs in oncology and neuroscience.

Key Points: 
  • Effective today, Dr. Berkowitz will lead the ongoing clinical development of Arvinas’ PROTAC® protein degrader programs in oncology and neuroscience.
  • “We are thrilled to have Dr. Berkowitz join Arvinas as we continue advancing multiple programs with the goal of improving the lives of patients with serious diseases,” said John Houston, Ph.D., Chairperson, President and Chief Executive Officer at Arvinas.
  • Dr. Berkowitz joins Arvinas from Bristol-Myers Squibb (BMS), where he was Senior Vice President, Development Unit Head, Hematology.
  • The option and restricted stock units were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas’ stock incentive plan.

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Retrieved on: 
Thursday, March 14, 2024
CD33, GSK, Patient, Macrophage, Society, CD3, CD47, DLL3, Therapy, Molecular Partners, TME, Partner, DRS, ASH, AML, SNMMI, Partnership, RDT, Radionuclide, Tetra, Novartis, HSCT, MHS, FTE, Exposition, Delta, Safety, SITC, Amgen, Hematopoietic stem cell transplantation, FAP, Disease, Nuclear medicine, Immunotherapy, District court, Neoplasm, EANM, Alpha particle, JNJ, Tumor microenvironment, Gene family, CD70, AACR, CD40, CHF, CD123, NK, Engineering, Antigen, Molecule, Annual general meeting, Toxicity, CD16, B cell, Conference, MBA, DARPin, Data, Molecular imaging, Pharmaceutical industry

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.
  • “2023 was a year of successful innovation and execution on our strategy, focusing on novel mechanisms that we believe only DARPin therapies can deliver.
  • In addition to the above updates, Molecular Partners continued to progress its RDT portfolio of projects in partnership with Novartis.
  • In the financial year 2023, Molecular Partners recognized total revenues and other income of CHF 7.0 million (2022: CHF 189.6 million) and incurred total expenses of CHF 68.1 million (2022: CHF 73.0 million).

IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon

Retrieved on: 
Thursday, March 14, 2024
Nephrology, Indoor Living, Novartis, Patient, Alnylam Pharmaceuticals, Perception, SGLT2, Immunoglobulin A, Budesonide, NDA, Record, Breakthrough therapy, UPCR, Atrasentan, Kidney, EGFR, Alexion, FDA, CHMP, Physician, Health, Pharmaceutical industry

For several years, Spherix Global Insights has been closely tracking the IgAN market and recently released its fourth annual US patient chart audit study.

Key Points: 
  • For several years, Spherix Global Insights has been closely tracking the IgAN market and recently released its fourth annual US patient chart audit study.
  • Spherix is the leading authority on IgAN market dynamics and will continue to provide insight into how nephrologists are treating and approaching care for their IgAN patients.
  • Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits.
  • Insights reveal the “why” behind treatment decisions, include year over year trending to quantify key aspects of market evolution, and integrate specialists’ attitudinal & demographic data to highlight differences between stated and actual treatment patterns.

SMDG Announces Appointment of Industry Leader Dr. Zsuzsanna Devecseri to the Board of Directors

Retrieved on: 
Thursday, March 14, 2024
Research, Certification, Growth, Novartis, Patient, University, MD, MBA, Semmelweis University, Pleasure, Research and development, Corvinus University of Budapest, Marketing, Nursing

“It is with pleasure that I welcome Zsuzsanna, the Global Head, Medical Affairs, Oncology, Novartis, to our Board of Directors,” said Shadi Farhangrazi, Chief Executive Officer of SMDG and chairman of the board.

Key Points: 
  • “It is with pleasure that I welcome Zsuzsanna, the Global Head, Medical Affairs, Oncology, Novartis, to our Board of Directors,” said Shadi Farhangrazi, Chief Executive Officer of SMDG and chairman of the board.
  • “Not only is Zsuzsanna an exceptional leader, she is also a passionate physician and scientist.
  • Zsuzsanna and our team share a common vision of bringing transformative therapies to patients.”
    Dr. Devecseri added, “I am thrilled to join the team and the board of SMDG.
  • Dr. Devecseri has had the opportunity to build and lead high-performing, engaged teams, and has gained a deep understanding of healthcare systems globally.

3Daughters Announces Three New Appointments to Board of Directors

Retrieved on: 
Wednesday, March 13, 2024
Quotient, Thakeham, Alnylam Pharmaceuticals, CDMO, Birth, Labs, GSK plc, Pharmacy, University, Novartis, Dana–Farber Cancer Institute, IUD, University College London, Embryology, IND, MBA, Woman, Doctor of Philosophy, Intrauterine device, Therapy, Drug development, Allergan, Amersham plc, Takeda Oncology, Chief Justice of Hungary, Pharmacia, Birth control

Miles, Ph.D., and Sarah J. Stevens, Ph.D., to serve on the Company’s Board of Directors.

Key Points: 
  • Miles, Ph.D., and Sarah J. Stevens, Ph.D., to serve on the Company’s Board of Directors.
  • An IND for 3D-001 will be filed this year followed by a Phase 1 clinical trial.
  • Mary Beth Cicero, CEO of 3Daughters, expressed her enthusiasm about the new additions to the board: "We are incredibly excited to have the collective strengths of Michele, Sarah, and Vin on our Board of Directors.
  • With this first product, 3Daughters expects to disrupt the IUD market and establish a position as a major innovator in women's healthcare.

MMS Hires Pharmaceutical Industry Veteran James Zee for Global Biometrics Leadership in Europe Amid Strong Regional Growth

Retrieved on: 
Thursday, April 4, 2024
Data Management, Technology, Pharmaceutical, Professional Services, Biometrics, Medical Devices, Genetics, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Software, Data Analytics, Health, Research, MSD, American City Business Journals, Growth, AstraZeneca, Data science, Novartis, Patient, Roche, MMS, RWD, AI, Statistics, Data management, Drug development, NCE, FSP, Zee, Fine chemical

MMS, a leading, data-focused clinical research organization (CRO), announced today that the company has expanded its biometrics leadership within European operations by hiring James Zee as Director of Global Statistical Programming.

Key Points: 
  • MMS, a leading, data-focused clinical research organization (CRO), announced today that the company has expanded its biometrics leadership within European operations by hiring James Zee as Director of Global Statistical Programming.
  • Based in the United Kingdom (UK), Zee brings 25 years of experience across several leading pharmaceutical companies, including AstraZeneca, MSD, Novartis, Roche, and others.
  • With extended drug development experience, Zee helps to guide the statistical programming team at MMS to support some of the timely execution and evolving regulations for the development of NCEs.
  • Since 2020, the global biometrics CRO has experienced 133 percent growth in Europe.

WorkForce Software Announces Thirteenth Annual VISION Conference as Investments in Global Workforce Management Technology Increase for Employers in 2024

Retrieved on: 
Wednesday, April 3, 2024
Other Manufacturing, Technology, Human Resources, Other Retail, Professional Services, Software, Manufacturing, Data Management, Retail, Other Professional Services, Conference, Organization, Novartis, Blueprint, Internal, Transformation, Castle & Cooke, Behavior informatics, Future, Marketing, Workforce, Investment, Personality, Culture, Growth, WestRock, Management

WorkForce Software , the #1 rated workforce management solution for large employers, is excited to announce its WorkForce Software User Conference: VISION.

Key Points: 
  • WorkForce Software , the #1 rated workforce management solution for large employers, is excited to announce its WorkForce Software User Conference: VISION.
  • This is the thirteenth year for the annual VISION conference hosted by WorkForce Software.
  • Conference sessions, roundtables, and solution demonstrations will allow attendees to explore the value of modern workforce management technology and uncover best practices for ensuring adoption.
  • A sampling of customer driven sessions includes:
    Novartis' Journey to Smart Automation in Workforce Management: Join Novartis' exploration of smart automation in workforce management, focusing on technology, change management, and efficiency gains.

Pharmaceutical Industry Medical Affairs and Market Access Veteran John Byrd, PhD, MBA to Join AESARA as VP, Management Consulting

Retrieved on: 
Wednesday, April 3, 2024
Health Technology, Health Insurance, Other Health, Marketing, Pharmaceutical, Practice Management, Communications, Managed Care, Mental Health, General Health, Hospitals, Biotechnology, Alternative Medicine, AIDS, Health, GSK, Boehringer Ingelheim, Market access, Novartis, Management consulting, Communication

We are pleased to announce the appointment of John Byrd as VP, Management Consulting at AESARA, a digital-forward Value & Evidence agency that develops innovative and trusted solutions to power transformative market access.

Key Points: 
  • We are pleased to announce the appointment of John Byrd as VP, Management Consulting at AESARA, a digital-forward Value & Evidence agency that develops innovative and trusted solutions to power transformative market access.
  • Ruslan Horblyuk, Chief Strategic Consulting Officer at AESARA, said, "John brings an unmatched breadth and depth of Medical Affairs and Market Access expertise at a time when we are focused on expanding our Management Consulting portfolio and capabilities at AESARA.
  • In his prior roles, John set the vision and strategic direction to ensure effective communication and implementation of value evidence, population health management and quality improvement programs.
  • I look forward to helping the company expand the capabilities within management consulting while continuing to deliver bold, innovative, and transformative solutions to our clients,” said John Byrd.

DIA 2024 Global Annual Meeting Welcomes Life Sciences Leaders to Confront Emerging Challenges in Healthcare

Retrieved on: 
Tuesday, April 2, 2024
Medical Devices, FDA, Health, Health Technology, General Health, Pharmaceutical, Eli Lilly, Combination, DCT, Microsoft Research, Artificiality, Trust (social science), GSK, Novartis, Patient, Food and Drug Administration, Artificial intelligence, USS Midway, AI, EMA, Merck & Co., Medicine, European Medicines Agency, Johnson & Johnson, Ecosystem, Drug development, Pharmacovigilance, Food, DIA, Student, Diamond, DEI, Medical device

The ethical use of artificial intelligence (AI) in healthcare, the development of advanced therapies, and other emerging regulatory and scientific challenges demand in-depth discussion as DIA , a global organization of life sciences professionals, accepts registrations for the DIA 2024 Global Annual Meeting , to be held June 16-20 in San Diego.

Key Points: 
  • The ethical use of artificial intelligence (AI) in healthcare, the development of advanced therapies, and other emerging regulatory and scientific challenges demand in-depth discussion as DIA , a global organization of life sciences professionals, accepts registrations for the DIA 2024 Global Annual Meeting , to be held June 16-20 in San Diego.
  • Thousands of industry representatives, regulators, government officials, academics, innovators, and patients will convene for the world's preeminent neutral life sciences forum — and the only thing missing is you.
  • "This year marks the 60th anniversary of DIA and the Global Annual Meeting, and we're celebrating by continuing to forge a bold future marked by innovation and impact," said Marwan Fathallah, DIA's President and Global Chief Executive.
  • — An interactive forum featuring U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) representatives discussing today's regulatory, scientific, and communication challenges.

KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer

Retrieved on: 
Monday, April 1, 2024
Other Manufacturing, Research, Manufacturing, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, CDMO, Novartis, Regulatory affairs, CGMP, Bayer, KBI, Chemical engineering, Multimedia, Amgen, Rensselaer Polytechnic Institute, Engineering

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality Officer, strengthening KBI’s expertise in Quality and Regulatory Affairs.

Key Points: 
  • KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality Officer, strengthening KBI’s expertise in Quality and Regulatory Affairs.
  • Peter will lead KBI’s Quality and Regulatory Affairs team, spearheading compliance and regulatory initiatives for customers worldwide and positioning KBI to provide the services, expertise, and leadership to partner with health authorities on regulatory policy.
  • "We have made a commitment to establishing KBI Biopharma as a thought leader and catalyst for change in Regulatory Affairs within the biopharma sector,” said J.D.
  • "Peter's addition to our team bolsters our expertise in quality and regulatory compliance and facilitates our continued transformation in support of our current and future customers.